LBO-004 Final results of MYR301: a randomised phase 3 study evaluating the efficacy and safety of up to 144 weeks of bulevirtide monotherapy for chronic hepatitis delta and 96 weeks of posttreatment follow-up

Heiner Wedemeyer, Soo Aleman, Antje Blank, Pietro Andreoné, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Viacheslav Morozov, Olga Sagalova, Tatiana Stepanova, Annemarie Berger, Sandra Ciesek, Amos Lichtman, Dmitry Manuilov, Renée-Claude Mercier, Sarah Arterburn, Florence Christian-Cox, Steve Tseng, Anu Osinusi, Julian Schulze zur Wiesch, Markus Cornberg, Stefan Zeuzem, Maurizia Rossana Brunetto, Pietro Lampertico